Penumbra, Inc. to Present at the Bank of America Merrill Lynch 2020 Health Care Conference

On April 29, 2020 Penumbra, Inc. (NYSE: PEN) reported that its management team is scheduled to present at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, 2020 (Press release, Penumbra, APR 29, 2020, View Source [SID1234556788]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

Bank of America Merrill Lynch 2020 Health Care Conference

Date:

Wednesday, May 13, 2020

Time:

2:20pm EDT / 11:20am PDT

A webcast of the presentation will be available by visiting the investors’ section of the company’s website at www.penumbrainc.com. The webcast will be available on the company’s website for at least two weeks following the event.

Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020

On April 29, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) reported it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes (Press release, Vanda Pharmaceuticals, APR 29, 2020, View Source [SID1234556787]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vanda will host a conference call at 4:30 PM ET on Wednesday, May 6, 2020, during which management will discuss the first quarter 2020 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 2583625.

The conference call will be broadcast simultaneously and archived on Vanda’s website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, May 6, 2020, beginning at 7:30 PM ET and will be accessible until Wednesday, May 13, 2020, at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 2583625.

Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020

On April 26, 2020 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) reported that the Company will release its 2020 first quarter financial results on Monday, May 11, 2020, before the market opens (Press release, Eagle Pharmaceuticals, APR 29, 2020, View Source [SID1234556786]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date

Monday, May 11, 2020

Time

8:30 a.m. EDT

Toll free (U.S.)

877-876-9173

International

785-424-1667

Webcast (live and replay)

www.eagleus.com, under the "Investor Relations" section

A replay of the conference call will be available for one week after the call’s completion by dialing 800-839-6803 (US) or 402-220-6056 (International) and entering conference call ID EGRXQ120. The webcast will be archived for 30 days at the aforementioned URL.

NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference

On April 29, 2020 NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., reported that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET (Press release, NantKwest, APR 29, 2020, View Source [SID1234556785]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the conference presentation will be available on the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days.

Dr. Soon-Shiong will present a clinical pipeline update with registrational strategies for NantKwest’s off-the-shelf natural killer cell-based therapeutics in combination with ImmunityBio’s N-803 Interleukin 15 (IL-15) ‘superagonist’ cytokine. He will also provide an update on the companies’ COVID-19 therapeutic and vaccine candidates.

McKesson Declares Quarterly Dividend April 29, 2020

On April 29, 2020 The Board of Directors of McKesson Corporation (NYSE:MCK) reported a regular dividend of 41 cents per share of common stock (Press release, McKesson, APR 29, 2020, View Source [SID1234556784]). The dividend will be payable on July 1, 2020, to stockholders of record on June 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!